Abstract

Fibrolamellar carcinoma (FLC) is a rare liver cancer. FLCs uniquely produce DNAJ-PKAc, a chimeric enzyme consisting of a chaperonin-binding domain fused to the Ca subunit of protein kinase A. Biochemical analyses of clinical samples reveal that a unique property of this fusion enzyme is the ability to recruit heat shock protein 70 (Hsp70). This cellular chaperonin is frequently up-regulated in cancers. Gene-editing of mouse hepatocytes generated disease-relevant AML12DNAJ-PKAc cell lines. Further analyses indicate that the proto-oncogene A-kinase anchoring protein-Lbc is up-regulated in FLC and functions to cluster DNAJ-PKAc/Hsp70 sub-complexes with a RAF-MEK-ERK kinase module. Drug screening reveals Hsp70 and MEK inhibitor combinations that selectively block proliferation of AML12DNAJ-PKAc cells. Phosphoproteomic profiling demonstrates that DNAJ-PKAc biases the signaling landscape toward ERK activation and engages downstream kinase cascades. Thus, the oncogenic action of DNAJ-PKAc involves an acquired scaffolding function that permits recruitment of Hsp70 and mobilization of local ERK signaling.

Data availability

There are no restrictions to the availability of our data. Raw mass spectrometry data has been uploaded to MassIVE, an NIH supported MS data repository (MSV000083167). Data will be made publicly available.

The following data sets were generated

Article and author information

Author details

  1. Rigney E Turnham

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. F Donelson Smith

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8080-7589
  3. Heidi L Kenerson

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Mitchell H Omar

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Martin Golkowski

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Irvin Garcia

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Renay Bauer

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Ho-Tak Lau

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Kevin M Sullivan

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Lorene K Langeberg

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3760-7813
  11. Shao-En Ong

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Kimberly J Riehle

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Raymond S Yeung

    Department of Surgery, University of Washington Medical Center, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. John D Scott

    Department of Pharmacology, University of Washington Medical Center, Seattle, United States
    For correspondence
    scottjdw@uw.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0367-8146

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119192)

  • John D Scott

Fibrolamellar Cancer Foundation

  • John D Scott

National Cancer Institute (R21CA201867)

  • Kimberly J Riehle

St. Baldrick's Foundation

  • Kimberly J Riehle

National Cancer Institute (R21CA177402)

  • Shao-En Ong

NIH Office of the Director (S10 OD021502)

  • Shao-En Ong

National Institutes of Health (2T32CA080416)

  • Rigney E Turnham

National Institute of Diabetes and Digestive and Kidney Diseases (F32DK121415)

  • Mitchell H Omar

Fibrolamellar Cancer Foundation

  • Raymond S Yeung

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2019, Turnham et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,145
    views
  • 350
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rigney E Turnham
  2. F Donelson Smith
  3. Heidi L Kenerson
  4. Mitchell H Omar
  5. Martin Golkowski
  6. Irvin Garcia
  7. Renay Bauer
  8. Ho-Tak Lau
  9. Kevin M Sullivan
  10. Lorene K Langeberg
  11. Shao-En Ong
  12. Kimberly J Riehle
  13. Raymond S Yeung
  14. John D Scott
(2019)
An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma
eLife 8:e44187.
https://doi.org/10.7554/eLife.44187

Share this article

https://doi.org/10.7554/eLife.44187

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Ana Patrícia Graça, Vadim Nikitushkin ... Gerald Lackner
    Research Article

    Mycofactocin is a redox cofactor essential for the alcohol metabolism of mycobacteria. While the biosynthesis of mycofactocin is well established, the gene mftG, which encodes an oxidoreductase of the glucose-methanol-choline superfamily, remained functionally uncharacterized. Here, we show that MftG enzymes are almost exclusively found in genomes containing mycofactocin biosynthetic genes and are present in 75% of organisms harboring these genes. Gene deletion experiments in Mycolicibacterium smegmatis demonstrated a growth defect of the ∆mftG mutant on ethanol as a carbon source, accompanied by an arrest of cell division reminiscent of mild starvation. Investigation of carbon and cofactor metabolism implied a defect in mycofactocin reoxidation. Cell-free enzyme assays and respirometry using isolated cell membranes indicated that MftG acts as a mycofactocin dehydrogenase shuttling electrons toward the respiratory chain. Transcriptomics studies also indicated remodeling of redox metabolism to compensate for a shortage of redox equivalents. In conclusion, this work closes an important knowledge gap concerning the mycofactocin system and adds a new pathway to the intricate web of redox reactions governing the metabolism of mycobacteria.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Santi Mestre-Fos, Lucas Ferguson ... Jamie HD Cate
    Research Article

    Stem cell differentiation involves a global increase in protein synthesis to meet the demands of specialized cell types. However, the molecular mechanisms underlying this translational burst and the involvement of initiation factors remains largely unknown. Here, we investigate the role of eukaryotic initiation factor 3 (eIF3) in early differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (NPCs). Using Quick-irCLIP and alternative polyadenylation (APA) Seq, we show eIF3 crosslinks predominantly with 3’ untranslated region (3’-UTR) termini of multiple mRNA isoforms, adjacent to the poly(A) tail. Furthermore, we find that eIF3 engagement at 3’-UTR ends is dependent on polyadenylation. High eIF3 crosslinking at 3’-UTR termini of mRNAs correlates with high translational activity, as determined by ribosome profiling, but not with translational efficiency. The results presented here show that eIF3 engages with 3’-UTR termini of highly translated mRNAs, likely reflecting a general rather than specific regulatory function of eIF3, and supporting a role of mRNA circularization in the mechanisms governing mRNA translation.